ABL Bio Inc
KOSDAQ:298380
ABL Bio Inc
Net Income (Common)
ABL Bio Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Net Income (Common)
-â‚©55.5B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
N/A
|
|
![]() |
Celltrion Inc
KRX:068270
|
Net Income (Common)
â‚©187.1B
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
7%
|
|
![]() |
SK Bioscience Co Ltd
KRX:302440
|
Net Income (Common)
-â‚©50.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Net Income (Common)
â‚©112B
|
CAGR 3-Years
20%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Net Income (Common)
â‚©88.8B
|
CAGR 3-Years
24%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
![]() |
Alteogen Inc
KOSDAQ:196170
|
Net Income (Common)
-â‚©2.9B
|
CAGR 3-Years
51%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
ABL Bio Inc
Glance View
ABL Bio, Inc. engages in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2018-12-19. The major products include anti-angiogenesis antibodies anti-tumor targeting antibodies, T cell engager bispecific antibodies (TCEs), dual immune cell targeting bispecific antibodies (DICs), novel immune cell targeting antibodies (NICs), brain disease dual antibodies, antibody-drug conjugates (ADCs) , among others.
See Also
What is ABL Bio Inc's Net Income (Common)?
Net Income (Common)
-55.5B
KRW
Based on the financial report for Dec 31, 2024, ABL Bio Inc's Net Income (Common) amounts to -55.5B KRW.
What is ABL Bio Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-8%
Over the last year, the Net Income (Common) growth was -1 998%. The average annual Net Income (Common) growth rates for ABL Bio Inc have been -8% over the past three years , -8% over the past five years .